COVID-19 Unveils Social Media Might: Is Pharma Listening Hard Enough?
Executive Summary
COVID-19 has generated a mind-boggling one billion-plus mentions on social media, unleashing unstructured big data rich in insights. Experts explain why pharma may well want to“listen in” more raptly to such conversations across therapy areas while shaping some aspects of business strategy.
You may also be interested in...
Star Power: How Celebrity Endorsement Is Shaping Pharma In India
Pharma in India draws on celebrity endorsement to spotlight specific disease conditions, with social media adding new dimensions to these efforts. But do these campaigns, now facing increasing disclosure scrutiny more widely, deliver a return on investment?
Star Power: How Celebrity Endorsement Is Shaping In India Pharma
Pharma in India draws on celebrity endorsement to spotlight specific disease conditions, with social media adding new dimensions to these efforts. But do these campaigns, now facing increasing disclosure scrutiny more widely, deliver a return on investment?
Takeda Vaccines Head: Peer Review Process For COVID-19 Vaccines Must Be 'Very Open'
The president of Takeda’s global vaccines business emphasizes the need to build trust and ensure that pharma is transparent about “what we will and will not know” at the time that COVID-19 vaccines are licensed.